FDA Considers Parsaclisib for Approval in FL, MZL, and MCLNovember 1st 2021
The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.
Study Underway to Evaluate New PD-1/CD3 Antibody in T-cell LymphomaOctober 21st 2021
A trial is currently recruiting across the US to investigate the safety of a new anti-PD-1/CD3 antibody for the treatment of relapsed or refractory T-cell lymphoma. It aims to enroll 86 patients.
New Option After Tisagenlecleucel for Patients With R/R LBCL Now in DevelopmentOctober 20th 2021
Following treatment with chimeric antigen receptor T-cell therapy, patients with relapsed or refractory large B-cell lymphoma require more options. Investigators are now evaluating an interleukin-17 agent.
Improving Risk/Benefit of Frontline Classical Hodgkin Lymphoma TreatmentOctober 17th 2021
Many options exist for advanced stage cHL, with varying degrees of toxicity. Ranjana H. Advani, MD, gives an overview of each during a presentation at the NCCN 2021 Virtual Congress: Hematologic Malignancies.
Survival Data is a Forefront Consideration in Choosing Third-Line DLBCL TreatmentOctober 2nd 2021
In an interview with Targeted Oncology, Patrick Connor Johnson, MD, discussed the top considerations taken into account by physicians when choosing a third-line therapy for diffuse large B-cell lymphoma.
Lasting Effects of Lymphoma TreatmentsSeptember 27th 2021
Ingrid Glimelius, MD, PhD, a senior lecturer and assistant professor in the Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology at Uppsala Universitet, discusses the lasting effects of lymphoma treatments.